TAGOVAMERAN

UNII:	BV8R57Y3YG
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	TAGOVAMERAN
GSRS Full Record:	BV8R57Y3YG i

2923496-70-0
RNA (recombinant 5′-(m7G-(5′→5′)-ppp-Am)-capped Venezuelan equine encephalitis virus RNA-dependent RNA polymerase [551-arginine,739-leucine] codon-optimized transgene plus severe acute respiratory syndrome coronavirus 2 spike glycoprotein [682-glycine,683-serine,685-serine,986-proline,987-proline] BA.4 and BA.5 variant precursor-specifying plus 5′- and 3′-untranslated flanking region-containing poly(A)-tailed messenger mRNA-2317), inner salt
Tagovameran
self-amplifying messenger RNA (mRNA), 5'-capped, encoding codonoptimised Venezuelan equine encephalitis virus (VEEV) RNA-dependent RNA polymerase complex (VEEV proteins nsP1, nsP2, nsP3 and nsP4) and a full-length codon-optimised pre-fusion stabilised conformation variant (K981P and V982P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike (S) glycoprotein BA.4/BA.5 variant (derived from GenBank ID: UVX18152) containing furin cleavageinactivating mutations (R677G, R678S and R680S), flanked by 5' and 3' untranslated regions and a 3' polyadenylation (poly(A) tail; generation of capped S glycoprotein mRNA is under control of a VEEV subgenomic promoter
tagovameran [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

TAGOVAMERAN

Synonyms and Mappings

Resources